Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Juyoung | - |
dc.contributor.author | Kim, Hyunah | - |
dc.contributor.author | Yim, Hyeon Woo | - |
dc.contributor.author | Kim, Ju Han | - |
dc.contributor.author | Lee, Suehyun | - |
dc.contributor.author | Kim, Hun-Sung | - |
dc.date.accessioned | 2022-04-19T08:44:50Z | - |
dc.date.available | 2022-04-19T08:44:50Z | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 0269-4727 | - |
dc.identifier.issn | 1365-2710 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/145970 | - |
dc.description.abstract | What is known and objectives Regardless of statin use, which is known to induce hyperglycaemia, comparative studies on the risk of new-onset diabetes mellitus (NODM) with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are needed. This study evaluated the effects of ACEIs and ARBs on NODM in the clinical setting. Methods This retrospective cohort study utilized electronic medical record data from Seoul St. Mary's Hospital and Seoul National University Hospital from 2009 to 2012. Patients who were prescribed ACEIs or ARBs for the first time (irrespective of concomitant statin use) were followed up for 5 years. Results and discussions A total of 11,703 patients were included, 24.9% (n = 2916) were taking ACEIs and 75.1% (n = 9189) were taking ARBs. Patients on ACEIs had a significantly lower incidence of NODM both with statin use (HR = 0.13, p < 0.001) and without (HR = 0.15, p = 0.009) than patients on ARBs. Age >= 60 years (HR = 1.49, p = 0.010), BMI >= 25 (HR = 1.96, p < 0.010), use of calcium channel blockers (HR = 1.47, p = 0.010), and diuretics (HR = 1.48, p = 0.010) were risk factors for NODM with statin use. What is new and conclusion Patients taking ACEIs are less likely to develop NODM than patients taking ARBs, irrespective of statin use. Patients' conditions, including the risk of NODM, should be considered before prescribing ACEIs or ARBs. Future randomized clinical trials are needed to clarify further the relationship between ACEIs and ARBs and their effect on NODM. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/jcpt.13544 | - |
dc.identifier.scopusid | 2-s2.0-85117218668 | - |
dc.identifier.wosid | 000708824100001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, v.47, no.1, pp 97 - 103 | - |
dc.citation.title | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | - |
dc.citation.volume | 47 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 97 | - |
dc.citation.endPage | 103 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
dc.subject.keywordPlus | HEART-FAILURE | - |
dc.subject.keywordPlus | SYSTEM | - |
dc.subject.keywordPlus | DRUGS | - |
dc.subject.keywordPlus | HYPERGLYCEMIA | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | NEBIVOLOL | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordAuthor | angiotensin receptor antagonists | - |
dc.subject.keywordAuthor | angiotensin-converting enzyme inhibitors | - |
dc.subject.keywordAuthor | diabetes mellitus | - |
dc.subject.keywordAuthor | hydroxymethylglutaryl-CoA reductase inhibitors | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.